Universal Health Services, Inc. (UHS) Stock Competitors & Peer Comparison
See (UHS) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| UHS | $144.92 | +0.16% | 8.9B | 5.96 | $23.95 | +0.56% |
| HCA | $363.35 | -2.05% | 81.5B | 12.65 | $29.03 | +0.81% |
| THC | $164.54 | -3.26% | 14.1B | 8.51 | $19.23 | N/A |
| SOLV | $77.87 | +2.68% | 13.2B | 9.36 | $8.17 | N/A |
| DVA | $194.19 | +2.30% | 12.1B | 18.10 | $10.38 | N/A |
| FMS | $20.95 | -0.45% | 11B | 10.82 | $1.90 | +4.21% |
| EHC | $102.41 | -0.31% | 10.1B | 17.39 | $5.84 | +0.73% |
| ENSG | $165.21 | +0.13% | 9.7B | 26.99 | $6.14 | +0.15% |
| OSH | $39.00 | +0.08% | 9.5B | -17.65 | -$2.21 | N/A |
| CHE | $425.96 | +0.74% | 5.5B | 22.75 | $18.34 | +0.57% |
Stock Comparison
UHS vs HCA Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, HCA has a market cap of 81.5B. Regarding current trading prices, UHS is priced at $144.92, while HCA trades at $363.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas HCA's P/E ratio is 12.65. In terms of profitability, UHS's ROE is +0.21%, compared to HCA's ROE of -1.23%. Regarding short-term risk, UHS is more volatile compared to HCA. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check HCA's competition here
UHS vs THC Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, THC has a market cap of 14.1B. Regarding current trading prices, UHS is priced at $144.92, while THC trades at $164.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas THC's P/E ratio is 8.51. In terms of profitability, UHS's ROE is +0.21%, compared to THC's ROE of +0.41%. Regarding short-term risk, UHS is less volatile compared to THC. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check THC's competition here
UHS vs SOLV Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, SOLV has a market cap of 13.2B. Regarding current trading prices, UHS is priced at $144.92, while SOLV trades at $77.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas SOLV's P/E ratio is 9.36. In terms of profitability, UHS's ROE is +0.21%, compared to SOLV's ROE of +0.31%. Regarding short-term risk, UHS is more volatile compared to SOLV. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check SOLV's competition here
UHS vs DVA Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, DVA has a market cap of 12.1B. Regarding current trading prices, UHS is priced at $144.92, while DVA trades at $194.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas DVA's P/E ratio is 18.10. In terms of profitability, UHS's ROE is +0.21%, compared to DVA's ROE of -1.33%. Regarding short-term risk, UHS is less volatile compared to DVA. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check DVA's competition here
UHS vs FMS Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, FMS has a market cap of 11B. Regarding current trading prices, UHS is priced at $144.92, while FMS trades at $20.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas FMS's P/E ratio is 10.82. In terms of profitability, UHS's ROE is +0.21%, compared to FMS's ROE of +0.07%. Regarding short-term risk, UHS is more volatile compared to FMS. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check FMS's competition here
UHS vs EHC Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, EHC has a market cap of 10.1B. Regarding current trading prices, UHS is priced at $144.92, while EHC trades at $102.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas EHC's P/E ratio is 17.39. In terms of profitability, UHS's ROE is +0.21%, compared to EHC's ROE of +0.25%. Regarding short-term risk, UHS is more volatile compared to EHC. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check EHC's competition here
UHS vs ENSG Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, ENSG has a market cap of 9.7B. Regarding current trading prices, UHS is priced at $144.92, while ENSG trades at $165.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas ENSG's P/E ratio is 26.99. In terms of profitability, UHS's ROE is +0.21%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, UHS is more volatile compared to ENSG. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check ENSG's competition here
UHS vs OSH Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, OSH has a market cap of 9.5B. Regarding current trading prices, UHS is priced at $144.92, while OSH trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas OSH's P/E ratio is -17.65. In terms of profitability, UHS's ROE is +0.21%, compared to OSH's ROE of +4.64%. Regarding short-term risk, UHS is more volatile compared to OSH. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check OSH's competition here
UHS vs CHE Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, CHE has a market cap of 5.5B. Regarding current trading prices, UHS is priced at $144.92, while CHE trades at $425.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas CHE's P/E ratio is 22.75. In terms of profitability, UHS's ROE is +0.21%, compared to CHE's ROE of +0.25%. Regarding short-term risk, UHS is less volatile compared to CHE. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check CHE's competition here
UHS vs LHCG Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, LHCG has a market cap of 5.3B. Regarding current trading prices, UHS is priced at $144.92, while LHCG trades at $169.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas LHCG's P/E ratio is 82.83. In terms of profitability, UHS's ROE is +0.21%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, UHS is more volatile compared to LHCG. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check LHCG's competition here
UHS vs MMED Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, MMED has a market cap of 3.5B. Regarding current trading prices, UHS is priced at $144.92, while MMED trades at $14.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas MMED's P/E ratio is -9.69. In terms of profitability, UHS's ROE is +0.21%, compared to MMED's ROE of -0.09%. Regarding short-term risk, UHS is less volatile compared to MMED. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check MMED's competition here
UHS vs AMED Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, AMED has a market cap of 3.3B. Regarding current trading prices, UHS is priced at $144.92, while AMED trades at $100.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas AMED's P/E ratio is 39.30. In terms of profitability, UHS's ROE is +0.21%, compared to AMED's ROE of +0.09%. Regarding short-term risk, UHS is more volatile compared to AMED. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check AMED's competition here
UHS vs OPCH Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, OPCH has a market cap of 3.2B. Regarding current trading prices, UHS is priced at $144.92, while OPCH trades at $20.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas OPCH's P/E ratio is 16.05. In terms of profitability, UHS's ROE is +0.21%, compared to OPCH's ROE of +0.15%. Regarding short-term risk, UHS is more volatile compared to OPCH. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check OPCH's competition here
UHS vs LFST Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, LFST has a market cap of 3B. Regarding current trading prices, UHS is priced at $144.92, while LFST trades at $7.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas LFST's P/E ratio is 129.33. In terms of profitability, UHS's ROE is +0.21%, compared to LFST's ROE of +0.02%. Regarding short-term risk, UHS is less volatile compared to LFST. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check LFST's competition here
UHS vs BKD Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, BKD has a market cap of 2.9B. Regarding current trading prices, UHS is priced at $144.92, while BKD trades at $12.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas BKD's P/E ratio is -13.85. In terms of profitability, UHS's ROE is +0.21%, compared to BKD's ROE of +401.19%. Regarding short-term risk, UHS is more volatile compared to BKD. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check BKD's competition here
UHS vs NHC Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, NHC has a market cap of 2.9B. Regarding current trading prices, UHS is priced at $144.92, while NHC trades at $185.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas NHC's P/E ratio is 23.28. In terms of profitability, UHS's ROE is +0.21%, compared to NHC's ROE of +0.12%. Regarding short-term risk, UHS is more volatile compared to NHC. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check NHC's competition here
UHS vs ACHC Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, ACHC has a market cap of 2.2B. Regarding current trading prices, UHS is priced at $144.92, while ACHC trades at $25.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas ACHC's P/E ratio is -2.00. In terms of profitability, UHS's ROE is +0.21%, compared to ACHC's ROE of -0.44%. Regarding short-term risk, UHS is less volatile compared to ACHC. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check ACHC's competition here
UHS vs SEM Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, SEM has a market cap of 2B. Regarding current trading prices, UHS is priced at $144.92, while SEM trades at $16.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas SEM's P/E ratio is 15.43. In terms of profitability, UHS's ROE is +0.21%, compared to SEM's ROE of +0.08%. Regarding short-term risk, UHS is more volatile compared to SEM. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check SEM's competition here
UHS vs AMEH Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, AMEH has a market cap of 1.8B. Regarding current trading prices, UHS is priced at $144.92, while AMEH trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas AMEH's P/E ratio is 39.25. In terms of profitability, UHS's ROE is +0.21%, compared to AMEH's ROE of +0.04%. Regarding short-term risk, UHS is less volatile compared to AMEH. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check AMEH's competition here
UHS vs ASTH Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, ASTH has a market cap of 1.8B. Regarding current trading prices, UHS is priced at $144.92, while ASTH trades at $36.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas ASTH's P/E ratio is 60.49. In terms of profitability, UHS's ROE is +0.21%, compared to ASTH's ROE of +0.04%. Regarding short-term risk, UHS is more volatile compared to ASTH. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check ASTH's competition here
UHS vs SGRY Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, SGRY has a market cap of 1.8B. Regarding current trading prices, UHS is priced at $144.92, while SGRY trades at $13.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas SGRY's P/E ratio is -23.34. In terms of profitability, UHS's ROE is +0.21%, compared to SGRY's ROE of -0.04%. Regarding short-term risk, UHS is more volatile compared to SGRY. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check SGRY's competition here
UHS vs MD Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, MD has a market cap of 1.8B. Regarding current trading prices, UHS is priced at $144.92, while MD trades at $21.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas MD's P/E ratio is 10.56. In terms of profitability, UHS's ROE is +0.21%, compared to MD's ROE of +0.20%. Regarding short-term risk, UHS is more volatile compared to MD. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check MD's competition here
UHS vs ADUS Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, ADUS has a market cap of 1.7B. Regarding current trading prices, UHS is priced at $144.92, while ADUS trades at $88.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas ADUS's P/E ratio is 16.69. In terms of profitability, UHS's ROE is +0.21%, compared to ADUS's ROE of +0.09%. Regarding short-term risk, UHS is more volatile compared to ADUS. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check ADUS's competition here
UHS vs AGL Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, AGL has a market cap of 1.4B. Regarding current trading prices, UHS is priced at $144.92, while AGL trades at $85.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas AGL's P/E ratio is -3.83. In terms of profitability, UHS's ROE is +0.21%, compared to AGL's ROE of -1.46%. Regarding short-term risk, UHS is less volatile compared to AGL. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check AGL's competition here
UHS vs AVAH Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, AVAH has a market cap of 1.4B. Regarding current trading prices, UHS is priced at $144.92, while AVAH trades at $6.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas AVAH's P/E ratio is 5.34. In terms of profitability, UHS's ROE is +0.21%, compared to AVAH's ROE of +2.41%. Regarding short-term risk, UHS is more volatile compared to AVAH. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check AVAH's competition here
UHS vs HCSG Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, HCSG has a market cap of 1.4B. Regarding current trading prices, UHS is priced at $144.92, while HCSG trades at $20.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas HCSG's P/E ratio is 21.31. In terms of profitability, UHS's ROE is +0.21%, compared to HCSG's ROE of +0.14%. Regarding short-term risk, UHS is more volatile compared to HCSG. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check HCSG's competition here
UHS vs ARDT Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, ARDT has a market cap of 1.3B. Regarding current trading prices, UHS is priced at $144.92, while ARDT trades at $7.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas ARDT's P/E ratio is 9.76. In terms of profitability, UHS's ROE is +0.21%, compared to ARDT's ROE of +0.09%. Regarding short-term risk, UHS is less volatile compared to ARDT. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check ARDT's competition here
UHS vs CMPS Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, CMPS has a market cap of 1.3B. Regarding current trading prices, UHS is priced at $144.92, while CMPS trades at $12.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas CMPS's P/E ratio is -4.25. In terms of profitability, UHS's ROE is +0.21%, compared to CMPS's ROE of -1.51%. Regarding short-term risk, UHS is less volatile compared to CMPS. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check CMPS's competition here
UHS vs BKDT Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, BKDT has a market cap of 1.2B. Regarding current trading prices, UHS is priced at $144.92, while BKDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas BKDT's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.21%, compared to BKDT's ROE of +401.19%. Regarding short-term risk, UHS is more volatile compared to BKDT. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check BKDT's competition here
UHS vs AMN Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, AMN has a market cap of 1.2B. Regarding current trading prices, UHS is priced at $144.92, while AMN trades at $29.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas AMN's P/E ratio is -35.22. In terms of profitability, UHS's ROE is +0.21%, compared to AMN's ROE of -0.05%. Regarding short-term risk, UHS is less volatile compared to AMN. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check AMN's competition here
UHS vs PNTG Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, PNTG has a market cap of 1.1B. Regarding current trading prices, UHS is priced at $144.92, while PNTG trades at $30.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas PNTG's P/E ratio is 35.87. In terms of profitability, UHS's ROE is +0.21%, compared to PNTG's ROE of +0.09%. Regarding short-term risk, UHS is less volatile compared to PNTG. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check PNTG's competition here
UHS vs INNV Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, INNV has a market cap of 980M. Regarding current trading prices, UHS is priced at $144.92, while INNV trades at $7.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas INNV's P/E ratio is -90.25. In terms of profitability, UHS's ROE is +0.21%, compared to INNV's ROE of -0.09%. Regarding short-term risk, UHS is more volatile compared to INNV. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check INNV's competition here
UHS vs USPH Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, USPH has a market cap of 951.9M. Regarding current trading prices, UHS is priced at $144.92, while USPH trades at $61.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas USPH's P/E ratio is 125.10. In terms of profitability, UHS's ROE is +0.21%, compared to USPH's ROE of +0.00%. Regarding short-term risk, UHS is less volatile compared to USPH. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check USPH's competition here
UHS vs TALK Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, TALK has a market cap of 874.4M. Regarding current trading prices, UHS is priced at $144.92, while TALK trades at $5.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas TALK's P/E ratio is 130.50. In terms of profitability, UHS's ROE is +0.21%, compared to TALK's ROE of +0.01%. Regarding short-term risk, UHS is more volatile compared to TALK. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check TALK's competition here
UHS vs FSHCX Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, FSHCX has a market cap of 816.7M. Regarding current trading prices, UHS is priced at $144.92, while FSHCX trades at $104.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas FSHCX's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.21%, compared to FSHCX's ROE of N/A. Regarding short-term risk, UHS is more volatile compared to FSHCX. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check FSHCX's competition here
UHS vs EHAB Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, EHAB has a market cap of 706.9M. Regarding current trading prices, UHS is priced at $144.92, while EHAB trades at $13.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas EHAB's P/E ratio is -197.14. In terms of profitability, UHS's ROE is +0.21%, compared to EHAB's ROE of -0.01%. Regarding short-term risk, UHS is more volatile compared to EHAB. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check EHAB's competition here
UHS vs SNDA Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, SNDA has a market cap of 673.4M. Regarding current trading prices, UHS is priced at $144.92, while SNDA trades at $32.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas SNDA's P/E ratio is -5.77. In terms of profitability, UHS's ROE is +0.21%, compared to SNDA's ROE of -0.35%. Regarding short-term risk, UHS is more volatile compared to SNDA. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check SNDA's competition here
UHS vs GMRS Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, GMRS has a market cap of 484.8M. Regarding current trading prices, UHS is priced at $144.92, while GMRS trades at $10.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas GMRS's P/E ratio is 66.47. In terms of profitability, UHS's ROE is +0.21%, compared to GMRS's ROE of N/A. Regarding short-term risk, UHS is less volatile compared to GMRS. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check GMRS's competition here
UHS vs TOI Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, TOI has a market cap of 458.9M. Regarding current trading prices, UHS is priced at $144.92, while TOI trades at $4.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas TOI's P/E ratio is -13.11. In terms of profitability, UHS's ROE is +0.21%, compared to TOI's ROE of +3.27%. Regarding short-term risk, UHS is less volatile compared to TOI. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check TOI's competition here
UHS vs MCTA Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, MCTA has a market cap of 445.6M. Regarding current trading prices, UHS is priced at $144.92, while MCTA trades at $29.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas MCTA's P/E ratio is 419.36. In terms of profitability, UHS's ROE is +0.21%, compared to MCTA's ROE of -2.33%. Regarding short-term risk, UHS is more volatile compared to MCTA. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check MCTA's competition here
UHS vs CCRN Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, CCRN has a market cap of 423.2M. Regarding current trading prices, UHS is priced at $144.92, while CCRN trades at $13.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas CCRN's P/E ratio is -4.29. In terms of profitability, UHS's ROE is +0.21%, compared to CCRN's ROE of -0.27%. Regarding short-term risk, UHS is more volatile compared to CCRN. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check CCRN's competition here
UHS vs CYH Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, CYH has a market cap of 391M. Regarding current trading prices, UHS is priced at $144.92, while CYH trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas CYH's P/E ratio is 0.81. In terms of profitability, UHS's ROE is +0.21%, compared to CYH's ROE of +0.06%. Regarding short-term risk, UHS is more volatile compared to CYH. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check CYH's competition here
UHS vs AIRS Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, AIRS has a market cap of 368.2M. Regarding current trading prices, UHS is priced at $144.92, while AIRS trades at $5.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas AIRS's P/E ratio is -30.71. In terms of profitability, UHS's ROE is +0.21%, compared to AIRS's ROE of -0.12%. Regarding short-term risk, UHS is less volatile compared to AIRS. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check AIRS's competition here
UHS vs AUNA Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, AUNA has a market cap of 335.3M. Regarding current trading prices, UHS is priced at $144.92, while AUNA trades at $4.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas AUNA's P/E ratio is 16.78. In terms of profitability, UHS's ROE is +0.21%, compared to AUNA's ROE of +0.04%. Regarding short-term risk, UHS is less volatile compared to AUNA. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check AUNA's competition here
UHS vs AONC Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, AONC has a market cap of 292.5M. Regarding current trading prices, UHS is priced at $144.92, while AONC trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas AONC's P/E ratio is -11.24. In terms of profitability, UHS's ROE is +0.21%, compared to AONC's ROE of +0.06%. Regarding short-term risk, UHS is more volatile compared to AONC. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check AONC's competition here
UHS vs CSU Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, CSU has a market cap of 223.7M. Regarding current trading prices, UHS is priced at $144.92, while CSU trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas CSU's P/E ratio is 0.67. In terms of profitability, UHS's ROE is +0.21%, compared to CSU's ROE of -0.51%. Regarding short-term risk, UHS is less volatile compared to CSU. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check CSU's competition here
UHS vs JYNT Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, JYNT has a market cap of 123.6M. Regarding current trading prices, UHS is priced at $144.92, while JYNT trades at $8.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas JYNT's P/E ratio is 96.33. In terms of profitability, UHS's ROE is +0.21%, compared to JYNT's ROE of +0.17%. Regarding short-term risk, UHS is less volatile compared to JYNT. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check JYNT's competition here
UHS vs NAKAW Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, NAKAW has a market cap of 116.4M. Regarding current trading prices, UHS is priced at $144.92, while NAKAW trades at $15.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas NAKAW's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.21%, compared to NAKAW's ROE of -0.85%. Regarding short-term risk, UHS is less volatile compared to NAKAW. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check NAKAW's competition here
UHS vs FVE Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, FVE has a market cap of 98.4M. Regarding current trading prices, UHS is priced at $144.92, while FVE trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas FVE's P/E ratio is -5.64. In terms of profitability, UHS's ROE is +0.21%, compared to FVE's ROE of -0.15%. Regarding short-term risk, UHS is more volatile compared to FVE. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check FVE's competition here
UHS vs KDLYW Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, KDLYW has a market cap of 96.5M. Regarding current trading prices, UHS is priced at $144.92, while KDLYW trades at $18.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas KDLYW's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.21%, compared to KDLYW's ROE of -0.85%. Regarding short-term risk, UHS is less volatile compared to KDLYW. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check KDLYW's competition here
UHS vs BTMD Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, BTMD has a market cap of 94.8M. Regarding current trading prices, UHS is priced at $144.92, while BTMD trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas BTMD's P/E ratio is 5.00. In terms of profitability, UHS's ROE is +0.21%, compared to BTMD's ROE of -0.23%. Regarding short-term risk, UHS is less volatile compared to BTMD. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check BTMD's competition here
UHS vs DCGO Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, DCGO has a market cap of 62M. Regarding current trading prices, UHS is priced at $144.92, while DCGO trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas DCGO's P/E ratio is -0.33. In terms of profitability, UHS's ROE is +0.21%, compared to DCGO's ROE of -0.89%. Regarding short-term risk, UHS is less volatile compared to DCGO. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check DCGO's competition here
UHS vs ALR Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, ALR has a market cap of 44.2M. Regarding current trading prices, UHS is priced at $144.92, while ALR trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas ALR's P/E ratio is -1.11. In terms of profitability, UHS's ROE is +0.21%, compared to ALR's ROE of -0.15%. Regarding short-term risk, UHS is more volatile compared to ALR. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check ALR's competition here
UHS vs PIII Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, PIII has a market cap of 42.1M. Regarding current trading prices, UHS is priced at $144.92, while PIII trades at $10.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas PIII's P/E ratio is -0.33. In terms of profitability, UHS's ROE is +0.21%, compared to PIII's ROE of +1.85%. Regarding short-term risk, UHS is less volatile compared to PIII. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check PIII's competition here
UHS vs IMAC Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, IMAC has a market cap of 33.1M. Regarding current trading prices, UHS is priced at $144.92, while IMAC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas IMAC's P/E ratio is -2.27. In terms of profitability, UHS's ROE is +0.21%, compared to IMAC's ROE of +1183.61%. Regarding short-term risk, UHS is more volatile compared to IMAC. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check IMAC's competition here
UHS vs CCEL Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, CCEL has a market cap of 28.7M. Regarding current trading prices, UHS is priced at $144.92, while CCEL trades at $3.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas CCEL's P/E ratio is -11.12. In terms of profitability, UHS's ROE is +0.21%, compared to CCEL's ROE of +0.16%. Regarding short-term risk, UHS is more volatile compared to CCEL. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check CCEL's competition here
UHS vs CANO-WT Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, CANO-WT has a market cap of 19.3M. Regarding current trading prices, UHS is priced at $144.92, while CANO-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas CANO-WT's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.21%, compared to CANO-WT's ROE of -1.49%. Regarding short-term risk, UHS is less volatile compared to CANO-WT. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check CANO-WT's competition here
UHS vs AIH Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, AIH has a market cap of 15.9M. Regarding current trading prices, UHS is priced at $144.92, while AIH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas AIH's P/E ratio is -2.78. In terms of profitability, UHS's ROE is +0.21%, compared to AIH's ROE of +1.16%. Regarding short-term risk, UHS is less volatile compared to AIH. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check AIH's competition here
UHS vs CANO Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, CANO has a market cap of 12.4M. Regarding current trading prices, UHS is priced at $144.92, while CANO trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas CANO's P/E ratio is -0.01. In terms of profitability, UHS's ROE is +0.21%, compared to CANO's ROE of -1.49%. Regarding short-term risk, UHS is less volatile compared to CANO. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check CANO's competition here
UHS vs FTRP Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, FTRP has a market cap of 9.8M. Regarding current trading prices, UHS is priced at $144.92, while FTRP trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas FTRP's P/E ratio is -1.22. In terms of profitability, UHS's ROE is +0.21%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, UHS is less volatile compared to FTRP. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check FTRP's competition here
UHS vs AMS Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, AMS has a market cap of 8.9M. Regarding current trading prices, UHS is priced at $144.92, while AMS trades at $1.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas AMS's P/E ratio is -6.14. In terms of profitability, UHS's ROE is +0.21%, compared to AMS's ROE of -0.06%. Regarding short-term risk, UHS is more volatile compared to AMS. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check AMS's competition here
UHS vs MODV Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, MODV has a market cap of 6.2M. Regarding current trading prices, UHS is priced at $144.92, while MODV trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas MODV's P/E ratio is -0.03. In terms of profitability, UHS's ROE is +0.21%, compared to MODV's ROE of +1.84%. Regarding short-term risk, UHS is more volatile compared to MODV. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check MODV's competition here
UHS vs GBNH Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, GBNH has a market cap of 5.5M. Regarding current trading prices, UHS is priced at $144.92, while GBNH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas GBNH's P/E ratio is -0.06. In terms of profitability, UHS's ROE is +0.21%, compared to GBNH's ROE of +15.74%. Regarding short-term risk, UHS is less volatile compared to GBNH. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check GBNH's competition here
UHS vs SYRA Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, SYRA has a market cap of 5.4M. Regarding current trading prices, UHS is priced at $144.92, while SYRA trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas SYRA's P/E ratio is -24.00. In terms of profitability, UHS's ROE is +0.21%, compared to SYRA's ROE of -0.08%. Regarding short-term risk, UHS is more volatile compared to SYRA. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check SYRA's competition here
UHS vs RHE-PA Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, RHE-PA has a market cap of 5.2M. Regarding current trading prices, UHS is priced at $144.92, while RHE-PA trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, UHS's ROE is +0.21%, compared to RHE-PA's ROE of +2.11%. Regarding short-term risk, UHS is less volatile compared to RHE-PA. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check RHE-PA's competition here
UHS vs RHE Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, RHE has a market cap of 5.2M. Regarding current trading prices, UHS is priced at $144.92, while RHE trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas RHE's P/E ratio is -1.79. In terms of profitability, UHS's ROE is +0.21%, compared to RHE's ROE of -0.36%. Regarding short-term risk, UHS is less volatile compared to RHE. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check RHE's competition here
UHS vs TOIIW Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, TOIIW has a market cap of 4.8M. Regarding current trading prices, UHS is priced at $144.92, while TOIIW trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas TOIIW's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.21%, compared to TOIIW's ROE of +3.27%. Regarding short-term risk, UHS is less volatile compared to TOIIW. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check TOIIW's competition here
UHS vs ATIP Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, ATIP has a market cap of 3M. Regarding current trading prices, UHS is priced at $144.92, while ATIP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas ATIP's P/E ratio is -0.03. In terms of profitability, UHS's ROE is +0.21%, compared to ATIP's ROE of +2.05%. Regarding short-term risk, UHS is less volatile compared to ATIP. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check ATIP's competition here
UHS vs IMACW Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, IMACW has a market cap of 1.7M. Regarding current trading prices, UHS is priced at $144.92, while IMACW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas IMACW's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.21%, compared to IMACW's ROE of +1.05%. Regarding short-term risk, UHS is less volatile compared to IMACW. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check IMACW's competition here
UHS vs CCM Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, CCM has a market cap of 694.6K. Regarding current trading prices, UHS is priced at $144.92, while CCM trades at $4.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas CCM's P/E ratio is -1.52. In terms of profitability, UHS's ROE is +0.21%, compared to CCM's ROE of +0.07%. Regarding short-term risk, UHS is less volatile compared to CCM. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check CCM's competition here
UHS vs TALKW Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, TALKW has a market cap of 686.8K. Regarding current trading prices, UHS is priced at $144.92, while TALKW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas TALKW's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.21%, compared to TALKW's ROE of +0.01%. Regarding short-term risk, UHS is less volatile compared to TALKW. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check TALKW's competition here
UHS vs MNDR Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, MNDR has a market cap of 657.8K. Regarding current trading prices, UHS is priced at $144.92, while MNDR trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas MNDR's P/E ratio is -0.31. In terms of profitability, UHS's ROE is +0.21%, compared to MNDR's ROE of -0.46%. Regarding short-term risk, UHS is less volatile compared to MNDR. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check MNDR's competition here
UHS vs NIVF Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, NIVF has a market cap of 527.2K. Regarding current trading prices, UHS is priced at $144.92, while NIVF trades at $0.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas NIVF's P/E ratio is 0.03. In terms of profitability, UHS's ROE is +0.21%, compared to NIVF's ROE of +0.33%. Regarding short-term risk, UHS is less volatile compared to NIVF. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check NIVF's competition here
UHS vs NVOS Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, NVOS has a market cap of 394.6K. Regarding current trading prices, UHS is priced at $144.92, while NVOS trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas NVOS's P/E ratio is -0.02. In terms of profitability, UHS's ROE is +0.21%, compared to NVOS's ROE of -0.81%. Regarding short-term risk, UHS is less volatile compared to NVOS. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check NVOS's competition here
UHS vs BACK Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, BACK has a market cap of 227.1K. Regarding current trading prices, UHS is priced at $144.92, while BACK trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas BACK's P/E ratio is -0.02. In terms of profitability, UHS's ROE is +0.21%, compared to BACK's ROE of +1.05%. Regarding short-term risk, UHS is more volatile compared to BACK. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check BACK's competition here
UHS vs PIIIW Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, PIIIW has a market cap of 49K. Regarding current trading prices, UHS is priced at $144.92, while PIIIW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas PIIIW's P/E ratio is -0.01. In terms of profitability, UHS's ROE is +0.21%, compared to PIIIW's ROE of +1.85%. Regarding short-term risk, UHS is less volatile compared to PIIIW. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check PIIIW's competition here
UHS vs NIVFW Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, NIVFW has a market cap of 44.3K. Regarding current trading prices, UHS is priced at $144.92, while NIVFW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas NIVFW's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.21%, compared to NIVFW's ROE of +0.33%. Regarding short-term risk, UHS is more volatile compared to NIVFW. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check NIVFW's competition here
UHS vs IONM Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, IONM has a market cap of 1.6K. Regarding current trading prices, UHS is priced at $144.92, while IONM trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas IONM's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.21%, compared to IONM's ROE of +5.28%. Regarding short-term risk, UHS is more volatile compared to IONM. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check IONM's competition here
UHS vs KND Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, KND has a market cap of 0. Regarding current trading prices, UHS is priced at $144.92, while KND trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas KND's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.21%, compared to KND's ROE of -0.53%. Regarding short-term risk, UHS is more volatile compared to KND. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check KND's competition here
UHS vs TVTY Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, TVTY has a market cap of 0. Regarding current trading prices, UHS is priced at $144.92, while TVTY trades at $32.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas TVTY's P/E ratio is 19.06. In terms of profitability, UHS's ROE is +0.21%, compared to TVTY's ROE of +1.75%. Regarding short-term risk, UHS is more volatile compared to TVTY. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check TVTY's competition here
UHS vs DCGOW Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, DCGOW has a market cap of 0. Regarding current trading prices, UHS is priced at $144.92, while DCGOW trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas DCGOW's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.21%, compared to DCGOW's ROE of -0.89%. Regarding short-term risk, UHS is less volatile compared to DCGOW. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check DCGOW's competition here
UHS vs NFH Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, NFH has a market cap of 0. Regarding current trading prices, UHS is priced at $144.92, while NFH trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas NFH's P/E ratio is -19.75. In terms of profitability, UHS's ROE is +0.21%, compared to NFH's ROE of -0.06%. Regarding short-term risk, UHS is more volatile compared to NFH. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check NFH's competition here
UHS vs HNGR Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, HNGR has a market cap of 0. Regarding current trading prices, UHS is priced at $144.92, while HNGR trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas HNGR's P/E ratio is 19.71. In terms of profitability, UHS's ROE is +0.21%, compared to HNGR's ROE of +0.52%. Regarding short-term risk, UHS is more volatile compared to HNGR. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check HNGR's competition here
UHS vs AFAM Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, AFAM has a market cap of 0. Regarding current trading prices, UHS is priced at $144.92, while AFAM trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas AFAM's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.21%, compared to AFAM's ROE of +0.06%. Regarding short-term risk, UHS is less volatile compared to AFAM. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check AFAM's competition here
UHS vs SLHGP Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, SLHGP has a market cap of 0. Regarding current trading prices, UHS is priced at $144.92, while SLHGP trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, UHS's ROE is +0.21%, compared to SLHGP's ROE of -0.48%. Regarding short-term risk, UHS is more volatile compared to SLHGP. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check SLHGP's competition here
UHS vs TLMD Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, TLMD has a market cap of 0. Regarding current trading prices, UHS is priced at $144.92, while TLMD trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas TLMD's P/E ratio is -1.60. In terms of profitability, UHS's ROE is +0.21%, compared to TLMD's ROE of -0.46%. Regarding short-term risk, UHS is more volatile compared to TLMD. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check TLMD's competition here
UHS vs SLHG Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, SLHG has a market cap of 0. Regarding current trading prices, UHS is priced at $144.92, while SLHG trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas SLHG's P/E ratio is -1.48. In terms of profitability, UHS's ROE is +0.21%, compared to SLHG's ROE of N/A. Regarding short-term risk, UHS is less volatile compared to SLHG. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check SLHG's competition here
UHS vs DVCR Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, DVCR has a market cap of 0. Regarding current trading prices, UHS is priced at $144.92, while DVCR trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas DVCR's P/E ratio is 28.34. In terms of profitability, UHS's ROE is +0.21%, compared to DVCR's ROE of -0.15%. Regarding short-term risk, UHS is more volatile compared to DVCR. This indicates potentially higher risk in terms of short-term price fluctuations for UHS.Check DVCR's competition here
UHS vs ATIP-WT Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, ATIP-WT has a market cap of 0. Regarding current trading prices, UHS is priced at $144.92, while ATIP-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas ATIP-WT's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.21%, compared to ATIP-WT's ROE of +2.05%. Regarding short-term risk, UHS is less volatile compared to ATIP-WT. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check ATIP-WT's competition here
UHS vs TLMDW Comparison June 2026
UHS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UHS stands at 8.9B. In comparison, TLMDW has a market cap of 0. Regarding current trading prices, UHS is priced at $144.92, while TLMDW trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UHS currently has a P/E ratio of 5.96, whereas TLMDW's P/E ratio is N/A. In terms of profitability, UHS's ROE is +0.21%, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, UHS is less volatile compared to TLMDW. This indicates potentially lower risk in terms of short-term price fluctuations for UHS.Check TLMDW's competition here